dsip 15mg | DSIP - Novara Peptides

Description

The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations

Typically, dosage cycles run from 6 to 12 weeks

Dopamine system protection: The peptide appears to protect against neurotoxicity and may help balance dopamine activity, with implications for conditions like Parkinson's disease

Omitting the EJ modifier causes the payer to treat each injection as the first in a new series, triggering quantity-limit denials on the second and third visits